Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Common Equity (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Common Equity readings, the most recent being $415.6 million for Q1 2026.

  • Quarterly Common Equity rose 89.11% to $415.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $415.6 million through Mar 2026, up 89.11% year-over-year, with the annual reading at $384.4 million for FY2025, 58.09% up from the prior year.
  • Common Equity hit $415.6 million in Q1 2026 for Oric Pharmaceuticals, up from $384.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $415.6 million in Q1 2026 and bottomed at $202.8 million in Q1 2023.
  • Average Common Equity over 5 years is $280.5 million, with a median of $253.1 million recorded in 2022.
  • The largest annual shift saw Common Equity crashed 33.14% in 2025 before it surged 89.11% in 2026.
  • Oric Pharmaceuticals' Common Equity stood at $222.4 million in 2022, then grew by 0.78% to $224.1 million in 2023, then grew by 8.49% to $243.1 million in 2024, then surged by 58.09% to $384.4 million in 2025, then rose by 8.12% to $415.6 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Common Equity are $415.6 million (Q1 2026), $384.4 million (Q4 2025), and $406.9 million (Q3 2025).